Browsing by Author "Chen, Weina"

Now showing 1 - 2 of 2
  • Thumbnail Image
    Item
    Primary Effusion Lymphoma: A Clinicopathological Study of 70 Cases
    (MDPI, 2021-02-19) Hu, Zhihong; Pan, Zenggang; Chen, Weina; Shi, Yang; Wang, Wei; Yuan, Ji; Wang, Endi; Zhang, Shanxiang; Kurt, Habibe; Mai, Brenda; Zhang, Xiaohui; Liu, Hui; Rios, Adan A.; Ma, Hilary Y.; Nguyen, Nghia D.; Medeiros, L. Jeffrey; Hu, Shimin; Pathology and Laboratory Medicine, School of Medicine
    Primary effusion lymphoma (PEL) is a rare type of large B-cell lymphoma associated with human herpesvirus 8 (HHV8) infection. Patients with PEL usually present with an effusion, but occasionally with an extracavitary mass. In this study, we reported a cohort of 70 patients with PEL: 67 men and 3 women with a median age of 46 years (range 26-91). Of these, 56 (80%) patients had human immunodeficiency virus (HIV) infection, eight were HIV-negative, and six had unknown HIV status. Nineteen (27%) patients had Kaposi sarcoma. Thirty-five (50%) patients presented with effusion only, 27 (39%) had an extracavitary mass or masses only, and eight (11%) had both effusion and extracavitary disease. The lymphoma cells showed plasmablastic, immunoblastic, or anaplastic morphology. All 70 (100%) cases were positive for HHV8. Compared with effusion-only PEL, patients with extracavitary-only PEL were younger (median age, 42 vs. 52 years, p = 0.001), more likely to be HIV-positive (88.9% vs. 68.6%, p = 0.06) and EBV-positive (76.9% vs. 51.9%, p = 0.06), and less often positive for CD45 (69.2% vs. 96.2%, p = 0.01), EMA (26.7% vs. 100%, p = 0.0005), and CD30 (60% vs. 81.5%, p = 0.09). Of 52 (50%) patients with clinical follow-up, 26 died after a median follow-up time of 40.0 months (range 0-96), and the median overall survival was 42.5 months. The median OS for patients with effusion-only and with extracavitary-only PEL were 30.0 and 37.9 months, respectively (p = 0.34), and patients with extracavitary-only PEL had a lower mortality rate at the time of last follow-up (35% vs. 61.5%, p = 0.07). The median OS for HIV-positive and HIV-negative patients were 42.5 and 6.8 months, respectively (p = 0.57), and they had a similar mortality rate of 50% at last follow-up. In conclusion, patients presenting with effusion-only versus extracavitary-only disease are associated with different clinicopathologic features. PEL is an aggressive lymphoma with a poor prognosis, regardless of extracavitary presentation or HIV status.
  • Thumbnail Image
    Item
    The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms
    (Springer, 2022) Khoury, Joseph D.; Solary, Eric; Abla, Oussama; Akkari, Yassmine; Alaggio, Rita; Apperley, Jane F.; Bejar, Rafael; Berti, Emilio; Busque, Lambert; Chan, John K. C.; Chen, Weina; Chen, Xueyan; Chng, Wee-Joo; Choi, John K.; Colmenero, Isabel; Coupland, Sarah E.; Cross, Nicholas C. P.; De Jong, Daphne; Elghetany, M. Tarek; Takahashi, Emiko; Emile, Jean-Francois; Ferry, Judith; Fogelstrand, Linda; Fontenay, Michaela; Germing, Ulrich; Gujral, Sumeet; Haferlach, Torsten; Harrison, Claire; Hodge, Jennelle C.; Hu, Shimin; Jansen, Joop H.; Kanagal-Shamanna, Rashmi; Kantarjian, Hagop M.; Kratz, Christian P.; Li, Xiao-Qiu; Lim, Megan S.; Loeb, Keith; Loghavi, Sanam; Marcogliese, Andrea; Meshinchi, Soheil; Michaels, Phillip; Naresh, Kikkeri N.; Natkunam, Yasodha; Nejati, Reza; Ott, German; Padron, Eric; Patel, Keyur P.; Patkar, Nikhil; Picarsic, Jennifer; Platzbecker, Uwe; Roberts, Irene; Schuh, Anna; Sewell, William; Siebert, Reiner; Tembhare, Prashant; Tyner, Jeffrey; Verstovsek, Srdan; Wang, Wei; Wood, Brent; Xiao, Wenbin; Yeung, Cecilia; Hochhaus, Andreas; Medical and Molecular Genetics, School of Medicine
    The upcoming 5th edition of the World Health Organization (WHO) Classification of Haematolymphoid Tumours is part of an effort to hierarchically catalogue human cancers arising in various organ systems within a single relational database. This paper summarizes the new WHO classification scheme for myeloid and histiocytic/dendritic neoplasms and provides an overview of the principles and rationale underpinning changes from the prior edition. The definition and diagnosis of disease types continues to be based on multiple clinicopathologic parameters, but with refinement of diagnostic criteria and emphasis on therapeutically and/or prognostically actionable biomarkers. While a genetic basis for defining diseases is sought where possible, the classification strives to keep practical worldwide applicability in perspective. The result is an enhanced, contemporary, evidence-based classification of myeloid and histiocytic/dendritic neoplasms, rooted in molecular biology and an organizational structure that permits future scalability as new discoveries continue to inexorably inform future editions.